Francois T Jenck

Francois T Jenck has a long and varied career in research and development of neuropharmacology. Francois T began their career in 1987 as a Research and Development Neuroscientist at Organon - AKZO Pharma. Francois T then moved to Hoffmann-La Roche in 1989, where they continued their work in R&D Neuro. In 2001, they joined Actelion Pharmaceuticals Ltd as the Head of Neuropharmacology Research in the R&D Labs. During their time there, they co-chaired a Neuroscience pipeline and published research on neuropeptides, immunomodulators, and vascular factors. In 2017, they moved to Idorsia Pharmaceuticals Ltd as the Senior Head of Neuropharmacology. While there, they were responsible for the clinical development program of the orexin receptor antagonist daridorexant, which was later approved by the FDA and EMA. In 2018, they joined R&D Neuro as the Chief Scientific Officer Axl.neuro. Most recently, in 2021, they began working at GliaPharm SA as the Chief Development Officer.

Francois T Jenck has a Postdoctoral Internship from Concordia University in Neurobiology and Neurosciences, and a Doctoral student from University of Strasbourg in Neurobiology and Neurosciences.